TRACON Pharmaceuticals Inc [NASDAQ: TCON] stock went on a downward path that fall over -24.79% on Monday, amounting to a one-week price decrease of less than -53.32%. The company report on April 8, 2024 at 9:10 AM that TRACON Pharmaceuticals Announces Reverse Stock Split. The
TRACON Pharmaceuticals Inc [NASDAQ: TCON] slipped around -0.2 points on Wednesday, while shares priced at $0.22 at the close of the session, down -47.18%. The company report on April 3, 2024 at 8:00 AM that TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal
TRACON Pharmaceuticals Inc [NASDAQ: TCON] surged by $0.0 during the normal trading session on while it closed the day at $0.46. The company report on March 5, 2024 at 4:02 PM that TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate
TRACON Pharmaceuticals Inc [NASDAQ: TCON] jumped around 0.02 points on Friday, while shares priced at $0.46 at the close of the session, up 4.49%. The company report on March 5, 2024 at 4:02 PM that TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results
TRACON Pharmaceuticals Inc [NASDAQ: TCON] closed the trading session at $0.36. The company report on March 5, 2024 at 4:02 PM that TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update. “We are on track to complete enrollment of 80
TRACON Pharmaceuticals Inc [NASDAQ: TCON] surged by $0.03 during the normal trading session on while it closed the day at $0.23. The company report on March 5, 2024 at 4:02 PM that TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate
TRACON Pharmaceuticals Inc [NASDAQ: TCON] gained 15.38% or 0.02 points to close at $0.20 with a heavy trading volume of 4434858 shares. The company report on December 20, 2023 at 8:00 AM that TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial.
© 2024, Powered by Smart TechOne
